Racial-ethnic diversity is lacking in psychedelic science. Efforts have been made to increase racial-ethnic representation among clinical trial participant populations, but much work remains. This column aims to describe this disparity, outline potential benefits of eliminating this disparity, and provide recommendations for achieving equity and justice within the research landscape of...
Prior data indicate limited ethnoracial diversity in studies testing psychedelic-assisted treatments. Regulatory approval for psychedelic treatments may be imminent given growing evidence for safety and efficacy in a variety of psychiatric conditions. Data on racial and ethnic inclusion rates in clinical psychedelic studies since 2018 have not been systematically reported to date. With the...